

**Closed Session Minutes**  
**of the**  
**Maryland Commission on Kidney Disease**  
**October 27, 2016**

Upon motion made in public session, Chairman Jaar called for adjournment of the Public Session into closed session to discuss the following item:

1. Discussion of Confidential Pricing of Auryxia and Velphoro drugs requested to be added to the Kidney Disease Program's Formulary- Authority: General Provisions Article, § 3-305(b)(7) and (13).
2. Discussion of Confidential Proposed Departmental Legislation for Session 2017- Authority: General Provisions Article, § 3-305(b) (13).

The Closed Session was called to order at 3:30 p.m. and held under the authority of § 3-305(b)(13) of the General Provisions Article.

In attendance, in addition to Chairman Jaar, were Commissioners' Collins, Hanes, Hargrove, Leon, Rayfield, Schiff, Segal, Wise, and Yospin were present.

In attendance representing Staff was Eva Schwartz, Executive Director and Donna Adcock, RN, Surveyor.

Also attending was Leslie Schulman, Commission Counsel.

**Item One**

The Commission discussed the request by Keryx Biopharmaceuticals to approve adding Auryxia to the Kidney Disease Program's (KDP) Formulary. After discussing the clinical benefits and cost factors in comparison to the other approved phosphate binder agent formulary drugs, the Commission unanimously voted to approve adding Auryxia to the formulary. Counsel advised the Commission that ratification of the vote will take place at the next Public Session. (Authority: General Provisions Article, §§ 3-305 (b)(7) and (13))

The Commission then discussed the request of Fresenius Medical Care Renal Therapies Group to approve adding Velphoro to the KDP Formulary. After discussing the clinical benefits and cost factors in comparison to other approved phosphate binder agent formulary drugs, the Commission voted to unanimously to approve adding Velphoro to the formulary. Counsel advised the Commission that ratification of the vote will take place at the next Public Session. (Authority: General Provisions Article, §§ 3-305 (b)(7) and (13))

**Item Two**

Eva Schwartz, Executive Director, summarized proposed DHMH legislation that is anticipated to be introduced by the Office of the Secretary during the 2017 Legislative Session. (Authority: General Provisions Article, §§ 3-305 (b) (13))

Upon Motion made, the Closed Session was adjourned at 4:18 p.m.